Skip to main content
PMC home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1980 Aug;100(2):327–338.

Pulmonary injury induced by C3a and C5a anaphylatoxins.

N P Stimler, T E Hugli, C M Bloor
PMCID: PMC1903546  PMID: 6967702

Abstract

Homogeneous anaphylatoxins C3a (human or porcine), C5a (porcine), and the porcine classic anaphylatoxin, a mixture of C5a and C5a des Arg, isolated from complement-activated serum, were shown to induce acute pulmonary injury in the guinea pig following intrabonchial instillation. The gross physiologic response to these factors is characterized by respiratory distress with rapid, shallow breathing. Administration of 8--17 micrograms/kg of porcine classic anaphylatoxin proved lethal in 50% of the animals treated. The acute response (less than 20 minutes after instillation) of pulmonary tissue to insult by the anaphylatoxins is characterized by constriction of the smooth muscle walls in both bronchioles and pulmonary arteries and by focal atelectasis. Aggregates of platelets and leukocytes in pulmonary vessels and in other organs such as the chambers of the heart were commonly observed after intrabronchial administration of the anaphylatoxins. Although C3a was never lethal in guinea pigs even when doses as high as 500 micrograms/kg were administered by the intrabronchial route, this anaphylatoxin did induce the same pattern of acute pulmonary injury as C5a. In vitro experiments employing guinea pig platelets indicated that these cells aggregate in the presence of 10(-10) M porcine C5a but are not affected by C3a (human or porcine) even at levels up to 10(-6) M. Hence, platelet aggregation as observed in vivo may be directly affected by C5a, but in the case of C3a, secondary mediators must be involved. Anaphylatoxin preparations were also shown to induce contraction of guinea pig lung strips in vitro: this effect was not inhibited by antihistamines at concentrations that blocked contraction to exogenous histamine. The in vivo response to anaphylatoxin could be blocked with high doses of the antihistamine chlorpheniramine but not by corresponding doses of diphenhydramine.

Full text

PDF
330

Images in this article

345Figure 2
on p.345
347Figure 3
on p.347
348Figure 4
on p.348
343Figure 1
on p.343

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bodammer G., Vogt W. Actions of anaphylatoxin on circulation and respiration of the guinea pig. Int Arch Allergy Appl Immunol. 1967;32(5):417–428. doi: 10.1159/000229953. [DOI] [PubMed] [Google Scholar]
  2. Chenoweth D. E., Rowe J. G., Hugli T. E. A modified method for chemotaxis under agarose. J Immunol Methods. 1979;25(4):337–353. doi: 10.1016/0022-1759(79)90026-7. [DOI] [PubMed] [Google Scholar]
  3. Cochrane C. G., Müller-Eberhard H. J. The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement. J Exp Med. 1968 Feb 1;127(2):371–386. doi: 10.1084/jem.127.2.371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Corbin N. C., Hugli T. E. The primary structure of porcine C3a anaphylatoxin. J Immunol. 1976 Sep;117(3):990–995. [PubMed] [Google Scholar]
  5. Desai U., Kreutzer D. L., Showell H., Arroyave C. V., Ward P. A. Acute inflammatory pulmonary reactions induced by chemotactic factors. Am J Pathol. 1979 Jul;96(1):71–83. [PMC free article] [PubMed] [Google Scholar]
  6. Fernandez H. N., Hugli T. E. Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. Polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a. J Biol Chem. 1978 Oct 10;253(19):6955–6964. [PubMed] [Google Scholar]
  7. Gerard C., Hugli T. E. Anaphylatoxin from the fifth component of porcine complement. Purification and partial chemical characterization. J Biol Chem. 1979 Jul 25;254(14):6346–6351. [PubMed] [Google Scholar]
  8. Grant J. A., Settle L., Whorton E. B., Dupree E. Complement-mediated release of histamine from human basophils. II. Biochemical characterization of the reaction. J Immunol. 1976 Aug;117(2):450–456. [PubMed] [Google Scholar]
  9. Grossklaus C., Damerau B., Lemgo E., Vogt W. Induction of platelet aggregation by the complement-derived peptides C3a and C5a. Naunyn Schmiedebergs Arch Pharmacol. 1976 Oct;295(1):71–76. doi: 10.1007/BF00509775. [DOI] [PubMed] [Google Scholar]
  10. Hagadorn J. E., Vazquez J. J., Kinney T. R. Immunopathologic studies of an experimental model resembling Goodpasture's syndrome. Am J Pathol. 1969 Oct;57(1):17–30. [PMC free article] [PubMed] [Google Scholar]
  11. Henson P. M., McCarthy K., Larsen G. L., Webster R. O., Giclas P. C., Dreisin R. B., King T. E., Shaw J. O. Complement fragments, alveolar macrophages, and alveolitis. Am J Pathol. 1979 Oct;97(1):93–110. [PMC free article] [PubMed] [Google Scholar]
  12. Hugli T. E. Human anaphylatoxin (C3a) from the third component of complement. Primary structure. J Biol Chem. 1975 Nov 10;250(21):8293–8301. [PubMed] [Google Scholar]
  13. Jacobs J. W., Rubin J. S., Hugli T. E., Bogardt R. A., Mariz I. K., Daniels J. S., Daughaday W. H., Bradshaw R. A. Purification, characterization, and amino acid sequence of rat anaphylatoxin (C3a). Biochemistry. 1978 Nov 14;17(23):5031–5038. doi: 10.1021/bi00616a027. [DOI] [PubMed] [Google Scholar]
  14. Kniker W. T., Cochrane C. G. The localization of circulating immune complexes in experimental serum sickness. The role of vasoactive amines and hydrodynamic forces. J Exp Med. 1968 Jan 1;127(1):119–136. doi: 10.1084/jem.127.1.119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lulich K. M., Mitchell H. W., Sparrow M. P. The cat lung strip as an in vitro preparation of peripheral airways: a comparison of beta-adrenoceptor agonists, autacoids and anaphylactic challenge on the lung strip and trachea. Br J Pharmacol. 1976 Sep;58(1):71–79. doi: 10.1111/j.1476-5381.1976.tb07694.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. McCombs R. P. Diseases due to immunologic reactions in the lungs. 2. N Engl J Med. 1972 Jun 8;286(23):1245–1252. doi: 10.1056/NEJM197206082862306. [DOI] [PubMed] [Google Scholar]
  17. Richerson H. B. Acute experimental hypersensitivity pneumonitis in the guinea pig. J Lab Clin Med. 1972 May;79(5):745–757. [PubMed] [Google Scholar]
  18. Scherzer H., Ward P. A. Lung and dermal vascular injury produced by preformed immune complexes. Am Rev Respir Dis. 1978 Mar;117(3):551–557. doi: 10.1164/arrd.1978.117.3.551. [DOI] [PubMed] [Google Scholar]
  19. Scherzer H., Ward P. A. Lung injury produced by immune complexes of varying composition. J Immunol. 1978 Sep;121(3):947–952. [PubMed] [Google Scholar]
  20. Shin H. S., Snyderman R., Friedman E., Mellors A., Mayer M. M. Chemotactic and anaphylatoxic fragment cleaved from the fifth component of guinea pig complement. Science. 1968 Oct 18;162(3851):361–363. doi: 10.1126/science.162.3851.361. [DOI] [PubMed] [Google Scholar]
  21. Tack B. F., Morris S. C., Prahl J. W. Fifth component of human complement: purification from plasma and polypeptide chain structure. Biochemistry. 1979 Apr 17;18(8):1490–1497. doi: 10.1021/bi00575a016. [DOI] [PubMed] [Google Scholar]
  22. Vallota E. H., Müller-Eberhard H. J. Formation of C3a and C5a anaphylatoxins in whole human serum after inhibition of the anaphylatoxin inactivator. J Exp Med. 1973 May 1;137(5):1109–1123. doi: 10.1084/jem.137.5.1109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Vazquez J. J. Immunopathologic aspects of lung disease. Arch Intern Med. 1970 Sep;126(3):471–474. [PubMed] [Google Scholar]
  24. Vogt W. Preparation and some properties of anaphylatoxin from hog serum. Biochem Pharmacol. 1968 May;17(5):727–733. doi: 10.1016/0006-2952(68)90009-9. [DOI] [PubMed] [Google Scholar]
  25. Waksman B. H. Chairman's summary: acute and chronic inflammation. Ann N Y Acad Sci. 1974;221:376–382. doi: 10.1111/j.1749-6632.1974.tb28238.x. [DOI] [PubMed] [Google Scholar]
  26. Wuepper K. D., Bokisch V. A., Müller-Eberhard H. J., Stoughton R. B. Cutaneous responses to human C 3 anaphylatoxin in man. Clin Exp Immunol. 1972 May;11(1):13–20. [PMC free article] [PubMed] [Google Scholar]
  27. ZUCKER M. B., BORRELLI J. Viscous metamorphosis produced by chilling and by clotting failure to find specific defect of viscous metamorphosis in PTA syndrome. Thromb Diath Haemorrh. 1960 Jun 15;4:424–434. [PubMed] [Google Scholar]
  28. da Silva W. D., Eisele J. W., Lepow I. H. Complement as a mediator of inflammation. 3. Purification of the activity with anaphylatoxin properties generated by interaction of the first four components of complement and its identification as a cleavage product of C'3. J Exp Med. 1967 Dec 1;126(6):1027–1048. doi: 10.1084/jem.126.6.1027. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES